Caring Brands, Inc. (NASDAQ:CABR) Short Interest Up 207.7% in June

Caring Brands, Inc. (NASDAQ:CABR) saw a significant growth in short interest during the month of June. As of June 15th, there was short interest totaling 63,992 shares, a growth of 207.7% from the May 31st total of 20,796 shares. Approximately 0.8% of the shares of the company are short sold. Based on an average daily trading volume, of 85,538 shares, the days-to-cover ratio is presently 0.7 days.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded shares of Caring Brands from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, June 11th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has an average rating of “Sell”.

Caring Brands Price Performance

CABR stock traded up $0.06 on Friday, reaching $1.21. The company’s stock had a trading volume of 37,154 shares, compared to its average volume of 80,184. Caring Brands has a 52 week low of $0.71 and a 52 week high of $5.35. The company has a debt-to-equity ratio of 0.03, a current ratio of 5.66 and a quick ratio of 5.62. The company has a market capitalization of $11.03 million and a P/E ratio of -1.90. The business has a fifty day simple moving average of $1.12.

Caring Brands (NASDAQ:CABR) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.27) earnings per share (EPS) for the quarter.

Institutional Trading of Caring Brands

An institutional investor recently bought a new stake in Caring Brands stock. Jane Street Group LLC acquired a new stake in Caring Brands, Inc. (NASDAQ:CABR) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 34,446 shares of the company’s stock, valued at approximately $30,000. Jane Street Group LLC owned approximately 0.25% of Caring Brands at the end of the most recent reporting period.

About Caring Brands

We are a wellness consumer products company. We offer several over-the-counter, or (OTC) and cosmetic, consumer products. Our method of operation is to ensure that (1) the mechanism of action of all products is established, (2) efficacy is determined through controlled clinical trials, (3) products are protected by issued and filed patents, and (4) products have acceptable commercial stability. Prior to its Q3 2022 commercial launch in India as a treatment for vitiligo and psoriasis, Photocil was briefly launched in the United States markets from December 2022 until February 2023, however, was subsequently removed from the market due to insufficient sales resulting from the lack of a dedicated sales and marketing team.